Clinical Trial Results:
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER’S DISEASE (AD)
Summary
|
|
EudraCT number |
2011-000914-21 |
Trial protocol |
BE GB DE ES PL |
Global completion date |
16 Jul 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Jul 2016
|
First version publication date |
10 Jul 2016
|
Other versions |
|
Summary report(s) |
IGIV 10%_161003_CSR_Synopsis_2014JUN17_Redacted_20160405 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.